🔗 Share this article

While America proceeds with sweeping changes to its vaccination schedules, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 shots throughout the pandemic and has zeroed in on potential fatalities after Covid immunization in her recent tenure at the FDA.

Planned Changes to Childhood Vaccine Program

Health officials planned to reveal radical changes to the childhood vaccine schedule in December, aligning the US with the Danish vaccine program, sources say – a major change that would place the US out of alignment with much of the world with no evidence for public health gain. The announcement has been pushed back until the coming year.

In place of the top vaccines chief, Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

The new acting director has frequently advocated for ending specific childhood immunization guidelines in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far public appearances, she has continued to focus on immunizations – typically the purview of Prasad, chief of the FDA’s CBER – rather than pharmaceutical oversight.

Concerns Over Expertise

Høeg has no apparent experience in drug development, oversight or leadership, which has been customary for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a large organization. She has no expertise in drug approvals.”

Past commissioners of CBER would “understand regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who ran the center have had.”

This division has an vast portfolio at the agency, she pointed out.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office clears thousands of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and other areas, and every single one must be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

There is also, a major management element to the job, which supervises in excess of 5,000 personnel. “It’s a enormous administrative position, if you do it right,” she concluded.

Response and Controversial Policies

In response to concerns about Høeg’s credentials and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a representative responded that the “inquiries stem from flawed premises”.

“Her resume matches the duties of her role,” the official explained, citing the months Dr. Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched expedited review system, a disputed expedited medication authorization process that apparently troubled her preceding directors. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Howard said. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent regulations of most medications, with the exception of shots.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more established, if troubling, history, some experts said. She released a analysis using unverified crowd-sourced reports to determine the incidence of heart inflammation after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the new federal leadership encompassed altering rules for novel immunizations and ending “optional” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an all-around dogmatist who starts off with her beliefs and tailors the evidence to accommodate the science in a very deceptive, untruthful way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined fellow contrarians, {like|